Buprenorphine Hydrochloride

盐酸丁丙诺啡

Report date: 2026/04/14 20:00:15

Base Information

Drug NameBuprenorphine Hydrochloride
Drug Alias Name丁丙诺啡盐酸盐Buprenorphine ER - Relmada TherapeuticsBuprenorphine extended release - Relmada TherapeuticsBuprenorphinum hydrochloridumBEMA long acting analgesic +[41] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMu opioid receptor agonistsKappa opioid receptor antagonistsδ-opioid receptor agonists +[4] 
TargetsMu opioid receptorKappa opioid receptorδ-opioid receptor +[4] 
Therapy Area/IndicationsIntervertebral disc diseaseSchizophreniaDepressive Disorder, Major +[33] 
Global Approved IndicationsOpioid-Related DisordersSubstance-Related DisordersPain
Approved Indications in ChinaSubstance-Related DisordersPain
Original Approved Country/TerritoryUnited States
Original Approved Date1981/12/29
Country/TerritoryCanadaUnited StatesDenmark +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesIndivior PLC
China Registration ClassN/A

Develop Information

Active CompaniesEgymedicalpediaEndo International PlcBdsi +[11] 
Inactive CompaniesMundipharma Research LtdThe Brigham and Women's HospitalPediatrix Medical Group Inc +[29] 
Active IndicationsSchizophreniaFractures, BoneSubstance Withdrawal Syndrome +[10] 
Inactive IndicationsIntervertebral disc diseaseDepressive Disorder, MajorDepressive Disorder +[23] 

Other Information

ATC CodeN02AE01N07BC01
Related LinksWikipediaDrugBankKEGG